Figure 4.
IBL-202 plus venetoclax decreases expression of CD49d and CXCR4 and impairs the migratory capacity of primary CLL cells. Changes in expression of CD49d and CXCR4 (A) and the migration of primary CLL cells down an SDF-1α gradient (n = 6) (B) were determined by flow cytometry after treatment with IBL-202 (1 μM) or venetoclax (10 nM) alone or in combination. Changes in antigen expression are presented using mean fluorescence intensity (MFI) values relative to levels in untreated cells. Flow cytometric plots from 1 representative patient sample illustrating the effects of IBL-202 and venetoclax, alone and in combination, on the number of viable cells migrating across a permeable support are shown. The number shown in the top left quadrant of each plot indicates the viable cell count under each condition.

IBL-202 plus venetoclax decreases expression of CD49d and CXCR4 and impairs the migratory capacity of primary CLL cells. Changes in expression of CD49d and CXCR4 (A) and the migration of primary CLL cells down an SDF-1α gradient (n = 6) (B) were determined by flow cytometry after treatment with IBL-202 (1 μM) or venetoclax (10 nM) alone or in combination. Changes in antigen expression are presented using mean fluorescence intensity (MFI) values relative to levels in untreated cells. Flow cytometric plots from 1 representative patient sample illustrating the effects of IBL-202 and venetoclax, alone and in combination, on the number of viable cells migrating across a permeable support are shown. The number shown in the top left quadrant of each plot indicates the viable cell count under each condition.

Close Modal

or Create an Account

Close Modal
Close Modal